- In July 2021, The US Food and Drug Administration has accepted AstraZeneca's Biologics License Application (BLA) for tezepelumab and granted it Priority Review for the treatment of asthma (FDA). AstraZeneca Plc is developing Tezepelumab in collaboration with Amgen Inc
